Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Debt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pulmonx (LUNG) EBIT Margin (2019 - 2025)

Pulmonx (LUNG) has disclosed EBIT Margin for 7 consecutive years, with 66.94% as the latest value for Q3 2025.

  • Quarterly EBIT Margin rose 237.0% to 66.94% in Q3 2025 from the year-ago period, while the trailing twelve-month figure was 62.38% through Sep 2025, up 1102.0% year-over-year, with the annual reading at 68.87% for FY2024, 2132.0% up from the prior year.
  • EBIT Margin for Q3 2025 was 66.94% at Pulmonx, down from 62.05% in the prior quarter.
  • The five-year high for EBIT Margin was 56.46% in Q4 2024, with the low at 145.28% in Q1 2022.
  • Average EBIT Margin over 5 years is 88.82%, with a median of 85.9% recorded in 2023.
  • Peak annual rise in EBIT Margin hit 20988bps in 2021, while the deepest fall reached -6433bps in 2021.
  • Over 5 years, EBIT Margin stood at 90.21% in 2021, then decreased by -5bps to 94.83% in 2022, then rose by 24bps to 72.2% in 2023, then increased by 22bps to 56.46% in 2024, then dropped by -19bps to 66.94% in 2025.
  • According to Business Quant data, EBIT Margin over the past three periods came in at 66.94%, 62.05%, and 64.62% for Q3 2025, Q2 2025, and Q1 2025 respectively.